Ian joined Brandon Capital in 2017.
Prior to joining Ian was head of Chemistry at the Cancer Therapeutics CRC, Melbourne. Ian worked for 10 years as a Medicinal Chemist and Project Leader with GlaxoSmithKline, UK and Zeneca, UK. Prior to this he carried out postdoctoral research at the Universities of South Paris, France and Sheffield, UK
Ian co-founded MycRx and Foray Therapeutics. He also currently advises; Azura Ophthalmics, Axelia Oncology, Certa Therapeutics, Ena Respiratory, OccuRx and Que Oncology.
Ian has a Bachelor of Science (Honours) from University of Nottingham and a PhD in Synthetic Organic Chemistry from the University of Nottingham. He is a Chartered Chemist (CChem) and Fellow of the Royal Society of Chemistry (FRSC).